SEC Form 10-K filed by Hudson Executive Investment Corp. III
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
of Class A common stock and one-fifth of one redeemable warrant |
||||
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
Non-accelerated filer |
☒ |
Smaller reporting company |
||||
Emerging growth company |
1 |
In September 2021, the registrant became a fully remote company. Accordingly, it does not maintain a principal office. |
Page |
||||||
1 |
||||||
2 |
||||||
Item 1. |
2 |
|||||
Item 1A. |
4 |
|||||
Item 1B. |
31 |
|||||
Item 2. |
31 |
|||||
Item 3. |
31 |
|||||
Item 4. |
31 |
|||||
31 |
||||||
Item 5. |
31 |
|||||
Item 6. |
32 |
|||||
Item 7. |
32 |
|||||
Item 7A. |
35 |
|||||
Item 8. |
35 |
|||||
Item 9. |
35 |
|||||
Item 9A. |
35 |
|||||
Item 9B. |
35 |
|||||
Item 9C. |
36 |
|||||
37 |
||||||
Item 10. |
37 |
|||||
Item 11. |
46 |
|||||
Item 12. |
46 |
|||||
Item 13. |
48 |
|||||
Item 14. |
50 |
|||||
51 |
||||||
Item 15. |
51 |
|||||
Item 16. |
53 |
|||||
54 |
||||||
54 |
• | our ability to complete our initial business combination; |
• | our expectations around the performance of the prospective target business or businesses; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors; |
• | our public securities’ potential liquidity and trading; |
• | the lack of a market for our securities; |
• | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
• | the trust account not being subject to claims of third parties; or |
• | our financial performance. |
Item 1. |
Business. |
Item 1A. |
Risk Factors. |
• | being a newly incorporated company with no operating history and no revenues; |
• | our ability to complete our initial business combination and risks arising from the uncertainty resulting from the COVID-19 pandemic; |
• | our public stockholders’ ability exercise redemption rights; |
• | the requirement that we complete our initial business combination within a certain time frame; |
• | the possibility that Nasdaq may delist our security from trading on its exchange; |
• | being declared an investment company under the Investment Company Act of 1940 (the “Investment Company Act”); |
• | complying with changing laws and regulations; |
• | our ability to select an appropriate target business or businesses and the performance of such target business or businesses; |
• | the pool of prospective target businesses available to us and the ability of our officers and directors to generate a number of potential business combination opportunities; |
• | the issuance of additional Class A common stock in connection with a business combination that may dilute the interest of our existing stockholders; |
• | the incentives to our sponsor, officers and directors to complete a business combination to avoid losing their entire investment in us if our initial business combination is not completed; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• | our ability to obtain additional financing to complete our initial business combination; |
• | our ability to amend the terms of our warrants in a manner that may be adverse to holders; |
• | our ability to redeem unexpired warrants prior to their exercise; |
• | our public securities’ potential liquidity and trading; |
• | provisions in our amended and restated certificate of incorporation and Delaware law that may have the effect of inhibiting a takeover of us and discouraging lawsuits against our directors and officers; |
• | we have identified a material weakness in our internal control over financial reporting, which could continue to adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner; and |
• | our management concluded that there is substantial doubt about our ability to continue as a “going concern.” |
• | restrictions on the nature of our investments; and |
• | restrictions on the issuance of securities, |
• | registration as an investment company with the SEC; |
• | adoption of a specific form of corporate structure; and |
• | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations that we are not currently subject to. |
• | may significantly dilute the equity interest of our existing investors; |
• | may subordinate the rights of holders of Class A common stock if shares of preferred stock are issued with rights senior to those afforded our Class A common stock; |
• | could cause a change in control if a substantial number of shares of Class A common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and |
• | may adversely affect prevailing market prices for our units, Class A common stock and/or warrants. |
• | solely dependent upon the performance of a single business, property or asset; or |
• | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
• | costs and difficulties inherent in managing cross-border business operations; |
• | rules and regulations regarding currency redemption; |
• | complex corporate withholding taxes on individuals; |
• | laws governing the manner in which future business combinations may be effected; |
• | exchange listing and/or delisting requirements; |
• | tariffs and trade barriers; |
• | regulations related to customs and import/export matters; |
• | local or regional economic policies and market conditions; |
• | unexpected changes in regulatory requirements; |
• | challenges in managing and staffing international operations; |
• | longer payment cycles; |
• | tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
• | currency fluctuations and exchange controls; |
• | rates of inflation; |
• | challenges in collecting accounts receivable; |
• | cultural and language differences; |
• | employment regulations; |
• | underdeveloped or unpredictable legal or regulatory systems; |
• | corruption; |
• | protection of intellectual property; |
• | social unrest, crime, strikes, riots and civil disturbances; |
• | regime changes and political upheaval; |
• | terrorist attacks and wars; including the conflict in Ukraine and the surrounding region; |
• | financial markets may be adversely affected by current or anticipated military conflict, including between Russia and Ukraine, terrorism, sanctions or other geopolitical events globally; and |
• | deterioration of political relations with the United States. |
• | a limited availability of market quotations for our securities; |
• | reduced liquidity for our securities; |
• | a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
• | a limited amount of news and analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
• | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
• | our inability to pay dividends on our Class A common stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
Item 1B. |
Unresolved Staff Comments. |
Item 2. |
Properties. |
Item 3. |
Legal Proceedings. |
Item 4. |
Mine Safety Disclosures. |
Item 5. |
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. |
Item 6. |
[Reserved] |
Item 9B. |
Other Information. |
Item 9C. |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. |
Item 10. |
Directors, Executive Officers and Corporate Governance. |
Name |
Age |
Title | ||||
Douglas L. Braunstein |
61 | President, Chairman of the Board of Directors | ||||
Douglas G. Bergeron |
61 | Chief Executive Officer and Director | ||||
Ira Mosberg |
45 | Chief Financial Officer | ||||
Barry L. Zubrow |
69 | Independent Director | ||||
Ashley Dombkowski |
51 | Independent Director | ||||
Douglas Renert |
54 | Independent Director |
• | overseeing the independent auditor, including retention, assessment of independence, evaluation of quality and performance and oversight of the work of the independent auditor; |
• | reviewing and discussing with management and the independent auditor financial statements and other financial disclosures; |
• | reviewing and discussing with management and the independent auditor (i) the quality and integrity of the financial statements, (ii) before the issuance of the audit report, the financial statements and related notes and (iii) “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” proposed to be included in the Company’s Annual Reports on Form 10-K, and annually preparing an audit committee report for inclusion where necessary in the proxy statement/prospectus relating to the annual meeting of stockholders and/or annual report of the Company; |
• | reviewing and discussing with management and the independent auditor the quarterly financial statements and related notes and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” proposed to be included in the Company’s Quarterly Reports on Form 10-Q; |
• | discussing with management and the independent auditor and, prior to issuance, reviewing and approving the Company’s earnings releases, including the financial information, use of any “pro forma” or “adjusted” non-GAAP information, and earnings guidance (if such is provided) to be disclosed in such releases; and reviewing on a quarterly basis all payments made to the sponsor, officers or directors, or to the Company’s or their affiliates; |
• | providing oversight of management’s design and maintenance of the Company’s internal control over financial reporting and disclosure controls and procedures; |
• | reviewing and discussing with management and the independent auditor the certifications and any related disclosures made by the Company’s Chief Executive Officer and Chief Financial Officer in the Company’s periodic reports about the results of their evaluation of the effectiveness of disclosure controls and procedures and any significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting, and any fraud involving management or other employees who have a significant role in the Company’s internal control over financial reporting, prior to the filing of the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q; |
• | reviewing with the independent auditor the responsibilities, budget, staffing, effectiveness and performance of the internal audit function, if any, including the structure, qualification and activities of the internal audit function and the scope of internal audit responsibilities in relation to the independent auditor’s duties; |
• | establishing clear policies regarding the hiring of employees and former employees of the Company’s independent auditor; |
• | reviewing and discussing with management, the head of the internal audit function, if any, and the independent auditor any significant risks or exposures and the Company’s policies and processes with respect to risk assessment, and assessing the steps management has taken to monitor and control such risks, except with respect to those risks for which oversight has been assigned to other committees of the Board or has been retained by the Board; |
• | reviewing the Company’s annual disclosures concerning the role of the Board in the risk oversight of the Company; |
• | reviewing and assessing with the chairman, co-chairman or co-executive chairman of the Board or outside counsel, as appropriate, legal and regulatory matters that may have a material impact on the Company’s financial statements; |
• | reviewing and recommending for Board approval the code of business conduct and ethics and any other appropriate compliance policies, and reviewing requests for waivers under the code of business conduct and ethics sought with respect to any executive officer or director; |
• | reviewing annually with the chairman, co- chairman or co-executive chairman of the Board or outside counsel, as appropriate, the scope, implementation and effectiveness of the ethics and compliance program, and any significant deviations by officers and employees from the code of business conduct and ethics or other compliance policies, and other matters pertaining to the integrity of management; |
• | establishing “whistleblowing” procedures for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and (ii) the confidential, anonymous submission by the Company’s employees of concerns regarding questionable accounting or auditing matters; |
• | reviewing and approving the Company’s decision to enter into swaps and other derivative transactions that are exempt from exchange-execution and clearance requirements under “end-user exception” regulations, and reviewing and discussing with management applicable Company policies governing the Company’s use of swaps subject to the “end-user exception”; |
• | reviewing and, if appropriate, approving or ratifying any related person transactions and other significant conflicts of interest, in each case in accordance with the Company’s code of business conduct and ethics and related party transactions policy; |
• | conducting an annual self-evaluation of the performance of the committee, including its effectiveness and compliance with its charter, and recommending to the Board such amendments of its charter as the committee deems appropriate; and |
• | reporting regularly to the Board on committee findings and recommendations and any other matters the committee deems appropriate or the Board requests, and maintaining minutes or other records of committee meetings and activities. |
• | establishing and reviewing the objectives of the Company’s management compensation programs and its basic compensation policies; |
• | reviewing and approving corporate goals and objectives relevant to the compensation of the Chief Executive Officer and other executive officers, including annual and long-term performance goals and objectives; |
• | reviewing and approving, subject to such further action of the Board as the Board shall determine, any employment, compensation, benefit or severance agreement with any executive officer; |
• | evaluating at least annually the performance of the Chief Executive Officer and other executive officers against corporate goals and objectives, including the annual performance objectives and, based on this evaluation, determining and approving, subject to such further action of the Board as the Board shall determine, the compensation (including any awards under any equity-based compensation or non-equity-based incentive compensation plan of the Company and any material perquisites) for the executive officers based on this evaluation; |
• | determining and approving the compensation level (including any awards under any equity-based compensation or non-equity-based incentive compensation plan of the Company and any material perquisites) for other members of senior management of the Company as the committee or the Board may from time to time determine to be appropriate; |
• | reviewing at least annually the compensation of other employees as the committee determines to be appropriate (including any awards under any equity-based compensation or non-equity-based incentive compensation plan of the Company and any material perquisites); |
• | reviewing on a periodic basis the Company’s management compensation programs, including any management incentive compensation plans as well as plans and policies pertaining to perquisites, to determine whether they are appropriate, properly coordinated and achieve their intended purpose(s), and recommending to the Board any appropriate modifications or new plans, programs or policies; |
• | reviewing, approving and recommending to the Board the adoption of any equity-based compensation plan for employees of, or consultants to, the Company and any modification of any such plan, and reviewing at least annually the awards made pursuant to such plans; |
• | administering the Company’s equity-based compensation plans for employees of and consultants to the Company as provided by the terms of such plans, including authorizing all awards made pursuant to such plans; |
• | reviewing, approving and recommending to the Board the adoption of any employee retirement plan, and other material employee benefit plan, and any material modification of any such plan; |
• | reviewing at least annually (i) the Company’s compensation policies and practices for executives, management employees and employees generally to assess whether such policies and practices could lead to excessive risk taking behavior and (ii) the manner in which any risks arising out of the Company’s compensation policies and practices are monitored and mitigated and adjustments necessary to address changes in the Company’s risk profile; |
• | with respect to any compensation consultant who has been engaged to make determinations or recommendations on the amount or form of executive or director compensation: (i) annually, or from time to time as the committee deems appropriate, assessing whether the work of any such compensation consultant (whether retained by the compensation committee or management) has raised any conflicts of interest; and (ii) reviewing the engagement and the nature of any additional services provided by such compensation consultant to the committee or to management, as well as all remuneration provided to such consultant; |
• | annually, or from time to time as the committee deems appropriate and, prior to retention of any advisers to the committee, assessing the independence of compensation consultants, legal and other advisers to the committee, taking into consideration all relevant factors the committee deems appropriate to such adviser’s independence, including factors specified in the listing standards of Nasdaq; |
• | reviewing and discussing with management the Compensation Discussion and Analysis disclosure required by SEC regulations and determining whether to recommend to the Board, as part of a report of the committee to the Board, that such disclosure be included in the Company’s Annual Report on Form 10-K and any proxy statement/prospectus for the election of directors; as part of this review, the committee shall consider the results of the most recent stockholder advisory vote on executive compensation (“say-on-pay” |
• | at least every six years or more frequently as appropriate, recommending to the Board the frequency with which the Company will conduct a say-on- |
• | reviewing the form and amount of director compensation at least annually, and making recommendations thereon to the Board; |
• | overseeing and monitoring other compensation related policies and practices of the Company, including: (i) the Company’s stock ownership guidelines for directors and executive officers; (ii) compliance by management with rules regarding equity-based compensation plans for employees and consultants pursuant to the terms of such plans, and the guidelines for issuance of awards as the Board or committee may establish; and (iii) the Company’s recoupment policy and procedures; |
• | overseeing stockholder communications relating to executive compensation and reviewing and making recommendations with respect to stockholder proposals related to compensation matters; |
• | conducting an annual self-evaluation of the performance of the committee, including its effectiveness and compliance with its charter, and recommending to the Board such amendments of its charter as the committee deems appropriate; |
• | reporting regularly to the Board on committee findings and recommendations and any other matters the committee deems appropriate or the Board requests, and maintaining minutes or other records of committee meetings and activities; |
• | from and after the completion of the Company’s initial business combination, in consultation with the Chief Executive Officer, annually reporting to the Board on succession planning, which shall include emergency Chief Executive Officer succession, Chief Executive Officer succession in the ordinary course and succession for other members of senior management, working with the entire Board to evaluate potential successors to the Chief Executive Officer; and |
• | undertaking such other responsibilities or tasks as the Board may delegate or assign to the committee from time to time. |
• | the corporation could financially undertake the opportunity; |
• | the opportunity is within the corporation’s line of business; and |
• | it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation. |
Individual |
Entity |
Entity’s Business |
Affiliation | |||
Douglas G. Bergeron |
Hudson Executive Capital LP | Investment Manager | Managing Partner | |||
HEC Management GP LLC | Investment Manager | Managing Partner | ||||
DGB Investments | Diversified holding company | Founder | ||||
Cantaloupe, Inc. | Automated retail | Chairman of the Board | ||||
United Language Group | Language translation/ interpretation | Chairman of the Board | ||||
Pipeworks Studios | Video game developer | Director |
Individual |
Entity |
Entity’s Business |
Affiliation | |||
Renters Warehouse | Property management/ investment | Director | ||||
Hudson Executive Investment Corp. II | Blank check company | Chief Executive Officer and Director | ||||
Douglas L. Braunstein |
Hudson Executive Capital LP | Investment Manager | Managing Partner | |||
HEC Management GP LLC | Investment Manager | Managing Partner | ||||
Hudson Executive Investment Corp. II | Blank check company | President, Chairman and Director | ||||
Talkspace, Inc. | Online therapy provider | Interim Chief Executive Officer and Chairman of the Board | ||||
Ira Mosberg |
Hudson Executive Capital LP | Investment Manager | Chief Financial Officer | |||
Hudson Executive Investment Corp. II | Blank check company | Chief Financial Officer | ||||
Barry L. Zubrow |
ITB LLC | Investment Management | Chief Executive Officer | |||
Canadian Imperial Bank of Commerce | Banking and Financial Services | Director | ||||
CIBC Bancorp USA Inc. | Banking and Financial Services | Director | ||||
CIBC Bank USA | Banking and Financial Services | Director | ||||
MIO Partners | Wealthy Advisory and Investment Management | Director | ||||
Accellix | Biotechnology | Director | ||||
Promontory Financial Group | Consulting firm | Advisory Board Member | ||||
Ashley Dombkowski |
Alladapt Immunotherapeutics | Biopharmaceutical company | Chief Executive Officer | |||
Douglas Renert |
Tandem Capital | Early-stage fund | Partner | |||
444 Capital | Venture capital firm | Managing Partner | ||||
Deako, Inc. | Light product manufacturer | Director | ||||
Shoe Lovers, Inc. | Media production | Director | ||||
Internet 404 Technologies, Inc. | Wholesale trade | Director | ||||
Hudson Executive Investment Corp. II | Blank check company | Director |
• | In the course of their other business activities, our directors and officers may become aware of investment and business opportunities that may be appropriate for presentation to us as well as the other entities with which they are affiliated, including HEIC II. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented. |
• | Our executive officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our executive officers are not obligated to contribute any specific number of hours per week to our affairs. |
• | Our initial stockholders purchased founder shares prior to the date of our Initial Public Offering and purchased Private Placement Warrants in a transaction that closed simultaneously with the closing of our Initial Public Offering. Our initial stockholders have entered into agreements with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares and any public shares they hold in connection with the completion of our initial business combination. The other members of our management team have entered into agreements similar to the ones entered into by our initial stockholders with respect to any public shares acquired by them in or after our Initial Public Offering. Additionally, our initial stockholders have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our initial business combination within the prescribed time frame. If we do not complete our initial business combination within the prescribed time frame, the Private Placement Warrants will expire worthless. Furthermore, our initial stockholders have agreed not to transfer, assign or sell any of their founder shares until the earlier of: (i) one year after the completion of our initial business combination and (ii) the date following the completion of our initial business combination on which we complete a liquidation, merger, capital stock exchange or other similar transaction that results in all of our stockholders having the right to exchange their common stock for cash, securities or other property. Notwithstanding the foregoing, if the closing price of our Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, the founder shares will be released from such lockup. Subject to certain limited exceptions, the Private Placement Warrants will not be transferable until 30 days following the completion of our initial business combination. Because each of our executive officers and director nominees will own common stock or warrants directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. |
• | Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to such proposed business combination. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
• | each of our executive officers, directors and director nominees; and |
• | all our executive officers and directors as a group. |
Name and Address of Beneficial Owner (1) |
Number of Shares Beneficially Owned (2) |
Approximate Percentage of Outstanding Common Stock |
||||||||||
Before Initial Public Offering |
After Initial Public Offering |
|||||||||||
HEC Sponsor III LLC (our sponsor) (3) |
14,925,000 | (4) |
99.5 | % | 20.0 | % | ||||||
Douglas L. Braunstein (3) |
— | — | — | |||||||||
Douglas G. Bergeron (3) |
— | — | — | |||||||||
Ira Mosberg |
— | — | — | |||||||||
Barry L. Zubrow |
25,000 | — | * | |||||||||
Ashley Dombkowski |
25,000 | — | * | |||||||||
Douglas Renert |
25,000 | — | * | |||||||||
All officers, directors and director nominees as a group (six individuals) |
75,000 | — | * |
* | Less than one percent. |
(1) | Because the Company operates remotely without a principal office, the business address of each of the following is also remote. |
(2) | Interests shown consist solely of founder shares, classified as Class B common stock. Such shares will automatically convert into Class A common stock concurrently with or immediately following the consummation of our initial business combination on a one-for-one |
(3) | Our sponsor is the record holder of the shares reported herein. HEC Master Fund LP (“HEC Master”) and Messrs. Braunstein and Bergeron are among the members of the sponsor and share voting and investment discretion with respect to the common stock held of record by the sponsor. Each of Messrs. Braunstein and Bergeron disclaims any beneficial ownership of the securities held by the sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Certain other members of our management team and Hudson Executive Capital’s network are also among members of the sponsor and may be entitled to distributions of founder shares and Private Placement Warrants held by the sponsor. |
(4) | Ms. Roni Frank resigned from the Board of Directors on March 2, 2022 and sold back her shares to the sponsor. |
Item 15. |
Exhibits, Financial Statement Schedules. |
(1) | Financial Statements: |
Page | ||||
F-2 |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
(2) | Financial Statement Schedules: |
(3) | Exhibits |
No. |
Description of Exhibit | |
101.DEF* |
Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* |
Inline XBRL Taxonomy Extension Labels Linkbase Document | |
101.PRE* |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS) |
* | Filed herewith. |
** | Furnished. |
Item 16. |
Form 10-K Summary. |
HUDSON EXECUTIVE INVESTMENT CORP. III | ||||||
Date: March 31, 2022 |
/s/ Douglas G. Bergeron | |||||
Name: |
Douglas G. Bergeron | |||||
Title: |
Chief Executive Officer and Director (Principal Executive Officer) |
Name |
Title |
Date | ||
/s/ Douglas G. Bergeron Douglas G. Bergeron |
Chief Executive Officer and Director (Principal Executive Officer) |
March 31, 2022 | ||
/s/ Douglas L. Braunstein Douglas L. Braunstein |
President, Chairman and Director |
March 31, 2022 | ||
/s/ Ira Mosberg Ira Mosberg |
Chief Financial Officer (Principal Financial and Accounting Officer) |
March 31, 2022 | ||
/s/ Barry L. Zubrow Barry L. Zubrow |
Director |
March 31, 2022 | ||
/s/Ashley Dombkowski Ashley Dombkowski |
Director |
March 31, 2022 | ||
/s/ Douglas Renert Douglas Renert |
Director |
March 31, 2022 |
F-2 |
||||
F-3 |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
December 31, |
||||||||
2021 |
2020 |
|||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash |
$ | $ | ||||||
Prepaid expenses |
||||||||
|
|
|
|
|||||
Total Current Assets |
||||||||
Deferred offering costs |
||||||||
Forward purchase agreement derivative asset |
||||||||
Marketable securities held in Trust Account |
||||||||
|
|
|
|
|||||
TOTAL ASSETS |
$ |
$ |
||||||
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY |
||||||||
Current liabilities |
||||||||
Accrued expenses |
$ | $ | ||||||
Accrued offering costs |
||||||||
Due to related party |
||||||||
Promissory note—related party |
||||||||
|
|
|
|
|||||
Total Current Liabilities |
||||||||
Warrant liabilities |
||||||||
Deferred underwriting fee payable |
||||||||
|
|
|
|
|||||
Total Liabilities |
||||||||
|
|
|
|
|||||
Commitments and Contingencies |
||||||||
Class A common stock subject to possible redemption, $ per share redemption value and no shares as of December 31, 2021 and 2020, respectively |
||||||||
Stockholders’ (Deficit) Equity |
||||||||
Preferred stock, $ |
||||||||
Class A common stock, $ par value; shares subject to possible redemption ) as of December 31, 2021 and 2020, respectively |
||||||||
Class B common stock, $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total Stockholders’ (Deficit) Equity |
( |
) |
||||||
|
|
|
|
|||||
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY |
$ |
$ |
||||||
|
|
|
|
Year Ended December 31, |
For the Period from August 18, 2020 (inception) through December 31, |
|||||||
2021 |
2020 |
|||||||
Formation and operating costs |
$ | $ | ||||||
Loss from operations |
( |
) |
( |
) | ||||
Other income: |
||||||||
Change in fair value of warrant liabilities and forward purchase agreement derivative asset |
— | |||||||
Transaction costs in connection with Initial Public Offerin g |
( |
) |
— |
|||||
Interest earned on marketable securities held in Trust Account |
— | |||||||
Total other income |
— | |||||||
Net income (loss) |
$ |
$ |
( |
) | ||||
Weighted average shares outstanding of Class A common stock |
— | |||||||
Basic net income per share, Class A common stock |
$ |
$ | — | |||||
Weighted average shares outstanding of Class B common stock |
||||||||
Basic net income (loss) per share, Class B common stock |
$ |
$ | ( |
) | ||||
Weighted average shares outstanding of Class B common stock |
||||||||
Diluted net income (loss) per share, Class B common stock |
$ |
$ | ( |
) | ||||
Class A Common Stock |
Class B Common Stock |
Additional Paid-in Capital |
Retained Earnings |
Total Stockholders’ Equity (Deficit) |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance—August 18, 2020 (Inception) |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Issuance of Class B common stock to Sponsor |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance—December 31, 2020 |
( |
) |
||||||||||||||||||||||||||
Sale of |
— | — | — | — | — | |||||||||||||||||||||||
Forfeiture of Founder Shares |
— | — | ( |
) | ( |
) | — | — | ||||||||||||||||||||
Accretion for Class A common shares to redemption amount |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Net income |
— | — | — | — | — | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance—December 31, 2021 |
$ | $ |
$ | $ |
( |
) |
$ |
( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
For the Period from August 18, 2020 (Inception) through December 31, |
|||||||
2021 |
2020 |
|||||||
Cash Flows from Operating Activities: |
||||||||
Net income (loss) |
$ | $ | ( |
) | ||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
||||||||
Change in fair value of warrant liabilities and forward purchase agreement |
( |
) | — | |||||
Transaction costs incurred in connection with Initial Public Offering |
— | |||||||
Interest earned on marketable securities held in Trust Account |
( |
) | — | |||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses and other current assets |
( |
) | — | |||||
Due to related party |
— | |||||||
Accrued expenses |
||||||||
|
|
|
|
|||||
Net cash used in operating activities |
( |
) |
( |
) | ||||
|
|
|
|
|||||
Cash Flows from Investing Activities: |
||||||||
Investment of cash into Trust Account |
( |
) | — | |||||
|
|
|
|
|||||
Net cash used in investing activities |
( |
) |
— | |||||
|
|
|
|
|||||
Cash Flows from Financing Activities: |
||||||||
Proceeds from sale of Units, net of underwriting discounts paid |
— | |||||||
Proceeds from sale of Private Placements Warrants |
— | |||||||
Proceeds from promissory note—related party |
— | |||||||
Repayment of promissory note—related party |
( |
) | — | |||||
Payment of offering costs |
( |
) | — | |||||
|
|
|
|
|||||
Net cash provided by financing activities |
||||||||
|
|
|
|
|||||
Net Change in Cash |
||||||||
Cash—Beginning of period |
— | |||||||
|
|
|
|
|||||
Cash—End of period |
$ |
$ |
||||||
|
|
|
|
|||||
Non-cash investing and financing activities: |
||||||||
Offering costs paid by Sponsor in exchange for issuance of Founder Shares |
$ | — | $ | |||||
|
|
|
|
|||||
Offering costs included in accrued offering costs |
$ | $ | ||||||
|
|
|
|
|||||
Offering costs paid through promissory note |
$ | $ | ||||||
|
|
|
|
|||||
Deferred underwriting fee payable |
$ | $ | — | |||||
|
|
|
|
As Previously Reported |
Adjustment |
As Restated |
||||||||||
Balance Sheet as of February 26, 2021 |
||||||||||||
Warrant and FPA liabilities |
$ | — | $ | $ | ||||||||
Class A common stock subject to possible redemption |
$ |
$ |
$ |
|||||||||
Class A common stock |
$ | $ | ( |
) | $ | — | ||||||
Additional paid-in capital |
$ | $ | ( |
) | $ | — | ||||||
Accumulated deficit |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Total Stockholders’ (Deficit) Equity |
$ | $ | ( |
) | $ | ( |
) |
Gross proceeds |
$ | |||
Less: |
||||
Proceeds allocated to Public Warrants |
( |
) | ||
Class A common stock issuance costs |
( |
) | ||
Plus: |
||||
Accretion of carrying value to redemption value |
||||
|
|
|||
Class A common stock subject to possible redemption |
$ | |||
|
|
Year Ended December 31, 2021 |
For the Period from August 18, 2020 (Inception) through December 31, 2020 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Basic net income per common share |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income (loss), as adjusted |
$ | $ | $ | $ | ( |
) | ||||||||||
Denominator: |
||||||||||||||||
Basic weighted average shares outstanding |
||||||||||||||||
Basic net income (loss) per common share |
$ | $ | $ | $ | ( |
) |
Year Ended December 31, 2021 |
For the Period from August 18, 2020 (Inception) through December 31, 2020 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Diluted net income per common share |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income (loss), as adjusted |
$ | $ | $ | $ | ||||||||||||
Denominator: |
||||||||||||||||
Diluted weighted average shares outstanding |
||||||||||||||||
Diluted net income (loss) per common share |
$ | $ | $ | $ | ( |
) |
• | in whole and not in part; |
• | at a price of $ |
• | upon not less than |
• | if, and only if, the closing price of the Class A common stock equals or exceeds $ a day period ending three business days before the Company sends the notice of redemption to the warrant holders. |
December 31, |
||||||||
2021 |
2020 |
|||||||
Deferred tax assets |
||||||||
Net operating loss carryforward |
$ | $ | ||||||
Startup/Organization Expenses |
||||||||
Total deferred tax assets |
||||||||
Valuation allowance |
( |
) | ( |
) | ||||
Deferred tax assets, net of allowance |
$ | $ | ||||||
Year Ended December 31, |
||||||||
2021 |
2020 |
|||||||
Federal |
||||||||
Deferred |
( |
) | ( |
) | ||||
Change in valuation allowance |
||||||||
Income tax provision |
$ | $ | ||||||
Year ended December 31, 2021 |
For the period from August 18, 2020 (inception) through December 31, 2020 |
|||||||
Statutory federal income tax rate |
% | % | ||||||
State taxes, net of federal tax benefit |
% | % | ||||||
Change in fair value of warrant liabilities |
( |
)% | % | |||||
Change in fair value of FPA |
( |
)% | % | |||||
Transaction costs incurred in connection with Initial Public Offering |
% | % | ||||||
Change in valuation allowance |
% | ( |
)% | |||||
Income tax provision |
% | % | ||||||
Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
Level |
Fair Value |
|||||||||
Assets: |
||||||||||
December 31, 2021 |
Marketable Securities held in Trust Account—Treasury Trust Money Market Fund |
1 | $ | |||||||
December 31, 2021 |
Forward Purchase Agreement Derivative Asset |
3 | $ | |||||||
Liabilities: |
||||||||||
December 31, 2021 |
Warrant Liabilities—Public Warrants |
1 | $ | |||||||
December 31, 2021 |
Warrant Liabilities—Private Placement Warrants |
2 | $ |
December 31, 2021 |
||||
Forward Purchase Price (per unit) |
$ | |||
Implied Stock Price Range (per share) |
$ | |||
Concluded Value of Private Warrants (1) |
$ | |||
Number of Warrants per unit |
||||
Concluded Unit Value |
$ | |||
Time to Initial Business Combination |
||||
Risk free rate |
% |
(1) |
Includes volatility of 12.8% and dividend of 0.0%. |
Private Placement |
Public |
Warrant Liabilities |
||||||||||
Fair value as of January 1, 2021 |
$ | $ | $ | |||||||||
Initial measurement on January 28, 2021 |
||||||||||||
Change in fair value |
( |
) | ( |
) | ( |
) | ||||||
Transfer to Level 1 |
— | ( |
) | ( |
) | |||||||
Transfer to Level 2 |
( |
) | — | ( |
) | |||||||
|
|
|
|
|
|
|||||||
Fair value as of December 31, 2021 |
$ | $ | — | $ | ||||||||
|
|
|
|
|
|
Forward Purchase Agreement Derivative |
||||
Fair value as of January 1, 2021 |
$ | |||
Initial measurement on February 23, 2021 |
( |
) | ||
Change in valuation inputs or other assumptions |
||||
|
|
|||
Fair value as of December 31, 2021 |
$ | |||
|
|